Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2318]

Novel therapeutic approaches in B-progenitor ALL

Dr Charles Mullighan - St. Jude's Children's Research Hospital, Memphis, USA

Novel therapeutic approaches in B-progenitor ALL ( Dr Charles Mullighan - St. Jude's Children's Research Hospital, Memphis, USA )

Latest concepts in frontline therapy for paediatric ALL

Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA

Latest concepts in frontline therapy for paediatric ALL ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )

Is enasidenib plus azacitidine better than with azacitidine alone for AML...

Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA

Is enasidenib plus azacitidine better than with azacitidine alone for AML patients? ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )

Lenalidomide maintenance for transplant eligible and transplant ineligible...

Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK

Lenalidomide maintenance for transplant eligible and transplant ineligible newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )

Dasatinib vs imatinib in the treatment of paediatric ALL

Dr Shuhong Shen - National Children's Medical Center, Shanghai, China

Dasatinib vs imatinib in the treatment of paediatric ALL ( Dr Shuhong Shen - National Children's Medical Center, Shanghai, China )

Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells...

Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern...

Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans ( Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switzerland )

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT...

Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo ( Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA )

Outcomes in patients with therapy-Related AML who achieved remission with CPX...

Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa...

Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis ( Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )

Selective oestrogen receptor degraders as treatment for ER positive/HER2...

Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium

Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer ( Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium )

SABCS 2019 highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

SABCS 2019 highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2...

Dr Miguel Martín - Universidad Complutense de Madrid, Madrid, Spain

The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2- metastatic breast cancer ( Dr Miguel Martín - Universidad Complutense de Madrid, Madrid, Spain )

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML...

Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )

More from ecancer